The Real-World Study of Immunogenicity and Safety of the Adjuvant Recombinant Vaccine against Varicella Zoster Virus in Patients with Immune-Mediated Inflammatory Diseases Treated with Janus Kinase Inhibitors

Background. The risk of herpes zoster reactivation is increased in immunocompromised patients, especially in those with immune-mediated inflammatory diseases (IMIDs) on Janus kinase inhibitor (JAKi) treatment. The recombinant subunit herpes zoster vaccine (RZV) is a non-live vaccine, recently approv...

Descripción completa

Detalles Bibliográficos
Autores principales: Esteban-Vazquez, Ana, Steiner, Martina, Castañeda, Elisabet, Andreu-Vazquez, Cristina, Thiussard, Israel J., Somodevilla, Angela, Gracia-Martínez, Moisés, Sánchez-Diaz, Rosa, García-Yubero, Cristina, Paredes-Romero, Maria Beatriz, Munoz-Fernández, Santiago
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610564/
https://www.ncbi.nlm.nih.gov/pubmed/37897012
http://dx.doi.org/10.3390/vaccines11101610

Ejemplares similares

Ejemplares similares